The expression of CD22 (Leu 14) and CD11c (LeuM5) in chronic lymphoproliferative disorders using two-color flow cytometric analysis.

The monoclonal antibodies (MoAbs) CD22 and CD11c recognize B-lymphocyte- and monocyte-associated antigens, respectively. Reports indicate that when these two MoAbs co-express, they represent a unique marker for hairy cell leukemia (HCL) although neither is specific for that disease. The authors evaluated the expression and diagnostic utility of CD22 and CD11C in specimens from 26 normal subjects, 29 patients, with various nonlymphoproliferative disorders (NLPDs), and 75 patients with different types of chronic lymphoproliferative disorders (CLDs) using two-color flow cytometric analysis of peripheral blood lymphocytes. Lymphocytes co-expressed CD22 and CD11c in less than or equal to 3% of the normal subjects and in less than or equal to 6% of the patients with NLPDs. These markers were expressed in greater than 10% of the lymphocytes of 46% (32/69) of the patients with B-cell CLDs: B-cell chronic-lymphocytic leukemia, 9/41; B-cell non-Hodgkin's lymphoma, 8/14; HCL, 11/11; B-cell lymphoproliferative disorder (NOS), 1/2; and B-cell prolymphocytic leukemia, 1/1. None (0/6) of the lymphocytes of patients with T-cell CLDs expressed greater than 10% CD22-positive (CD22+) or CD11c-positive (CD11c+) cells. The HCL cases demonstrated a unique CD22+CD11c+ fluorescence histogram pattern, distinct from other lymphoproliferative disorders, that was characterized by uniformly intense CD11c and CD22 fluorescence. Differences in the expression of the CD22+CD11C- and CD22+CD11C+ phenotypes between diagnostic groups were found, most notable was a paucity of CD22+CD11c+ cells in lymphocytes of patients with HCL. CD22 also had more variable expression than CD19 and HLA-DR in the cases of B-cell CLD. This study demonstrates that the CD22+CD11c+ phenotype is not unique to HCL but is a consistent feature of that disorder and that the immunofluorescence pattern of co-expression in HCL is diagnostically useful.

[1]  T. Barbui,et al.  Investigation of chronic lymphocytosis in adults. , 1988, American Journal of Clinical Pathology.

[2]  G. Inghirami,et al.  Differential expression of LFA-1 molecules in non-Hodgkin's lymphoma and lymphoid leukemia. , 1988, Blood.

[3]  G. Starkebaum,et al.  Large Granular Lymphocyte Leukemia: REPORT OF 38 CASES AND REVIEW OF THE LITERATURE , 1987, Medicine.

[4]  P. Hokland,et al.  A two-color flow cytometry assay for detection of hairy cells using monoclonal antibodies. , 1987, Blood.

[5]  R. Warnke,et al.  Immunophenotypic differences between dermatopathic lymphadenopathy and lymph node involvement in mycosis fungoides. , 1985, The American journal of pathology.

[6]  H. Stein,et al.  The differential diagnosis of hairy cell leukemia with a panel of monoclonal antibodies. , 1985, American journal of clinical pathology.

[7]  R. Savage,et al.  Antigenic phenotype of splenic hairy cells. , 1984, The American journal of medicine.

[8]  F. Sánchez‐Madrid,et al.  A human leukocyte differentiation antigen family with distinct alpha- subunits and a common beta-subunit: the lymphocyte function-associated antigen (LFA-1), the C3bi complement receptor (OKM1/Mac-1), and the p150,95 molecule , 1983, The Journal of experimental medicine.

[9]  T. Waldmann,et al.  Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[10]  B. Haynes,et al.  Phenotypic characterization of cutaneous T-cell lymphoma. Use of monoclonal antibodies to compare with other malignant T cells. , 1981, The New England journal of medicine.

[11]  J. Cawley,et al.  A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia. , 1980, Leukemia research.